We report here the logistic modeling of the epidemiologic differences between a diagnostic population and a screening population recruited for the study of optical technologies for cervical cancer detection.
INTRODUCTION
Cervical cancer is the second most common and third most deadly cancer among women worldwide, with an estimated 493,243 new cases and 273,505 deaths in 2002 alone, 1 and has been causally linked to human papillomavirus (HPV) infection. 2 Eighty-three percent of all cases occur in the developing world, 1 likely due to the absence of well-established screening programs to detect precancerous dysplasia. 3 With early detection, death from cervical cancer is preventable, and 5-year survival is approximately 92%. 4 Yet, despite this lifesaving advantage, such programs present a tremendous economic burden to society. Insinga et al 5 estimated that the annual cost of cervical HPVrelated disease amounted to $3.4 billion in the United States in 1998. A noticeable portion of this expense ($300 million) was devoted to "treating" false-positive findings on Papanicolaou smears. 5 It would therefore be frugal, especially in the developing world (or other low-resource settings), to preferentially screen the populations of women who are most susceptible to the development of this malignancy.
Additionally, more effective means of diagnosis and treatment (ideally simultaneously) would decrease not only the wait time associated with diagnosis, but also the overall number of health care visits required to treat preneoplastic lesions of the cervix. Our group has a keen interest in further developing optic technologies for the rapid diagnosis and treatment of cervical dysplasia. We have focused our attention on fluorescence and reflectance spectroscopy and have been able to show differences between normal and abnormal cervical tissue in vitro and in vivo using these techniques. The spectroscopic system used to measure fluorescence excitation-emission matrices was described in detail previously. 6, 7 Briefly, the system measures fluorescence emission spectra at 16 excitation wavelengths, ranging from 330 to 480 nm in 10-nm increments with a spectral resolution of 5 nm. The system incorporates a fiberoptic probe, a xenon arc lamp coupled with a monochromator to provide excitation light, and a polychromator and thermoelectrically cooled charge coupled device camera to record fluorescence intensity as a function of emission wavelength.
Real-time diagnosis of cervical dysplasia using these optical techniques could greatly advance medical treatment of women diagnosed with these conditions. In developed countries, this could greatly reduce the number of office visits and unnecessary biopsies. In developing countries, this could translate into the implementation of screening programs that do not rely on highly trained medical professionals.
Several risk factors for cervical cancer have been repeatedly identified, specifically, smoking, genital infections, parity, oral contraceptive (OC) use, age at the start of sexual activity, and number of lifetime partners. 8 However, the exact contribution of each to the natural history of disease is still unclear because study results to date have been inconclusive. Important to this process is identifying those factors that are more predictive of persistent HPV infection (ie, those at high-risk for the development of dysplasia or cancer). In this report, we attempt to address the controversies arising from conflicting studies through the logistic modeling of epidemiologic differences between a diagnostic population and a screening population recruited for the study of optical technologies for cervical cancer detection.
METHODS

Data Source
Epidemiologic data were obtained from a risk factor interview as a component of a multicenter Phase II clinical trial that used fluorescence and reflectance point spectroscopy to diagnose cervical disease. The trial was conducted at The University of Texas M.D. Anderson Cancer Center and the Lyndon Baines Johnson Harris County Hospital in Houston, Texas, as well as the British Columbia Cancer Agency in Vancouver, British Columbia, Canada. The trial began in 1999 and concluded in 2005 and enrolled women 18 years of age or older. Women who had had a hysterectomy or who were pregnant at the time of enrollment were ineligible. The institutional review board at each institution approved the protocols, and written consent was obtained from all participants.
Participants with abnormal findings on a recent or past Papanicolaou smear were grouped into the diagnostic (high-risk) population, whereas those with a history of normal findings on Papanicolaou smears and no cervical treatments were grouped into the screening (low-risk) population. Specific study procedures included a risk factor interview; a complete medical history; full physical and gynecologic examinations; regular and ThinPrep (Cytyc Corp., Marlborough, Massachusetts) Papanicolaou smears; cervical cultures; specimens for HPV typing; pan-colposcopy of the vulva, vagina, and cervix; spectroscopic measurements of the cervix; and biopsies. Each risk factor interview was conducted in a secluded area by a research nurse and qualified translator, if necessary. All other clinical procedures were performed by a nurse practitioner or study physician.
HPV Typing and Confirmation of Disease Status
HPV typing was completed through the use of Hybrid Capture II (Digene Corporation, Gaithersburg, Maryland) and quantitative polymerase chain reaction (PCR) for the most common highrisk types (HPV 16 and 18). Cervical samples for PCR were placed in phosphate-buffered saline with 0.05% sodium azide and stored at Ϫ20°C. DNA was extracted using a commercially available kit (Qiagen, Valencia, California). PCR for glycerol-3phosphate dehydrogenase was performed to ensure the integrity of the DNA. Successful amplification was measured by the detection of a 450base pair product. PCR for HPV DNA was performed with two L1 primers (MY-9 and MY-11), which recognize a 450-base pair region in the L1 open reading frame of at least 28 different types of HPV. 9 PCR products were transferred onto nylon membranes (Bio-Rad, Hercules, California) and separately hybridized to 32 P-labeled consensus and type specific HPV 16 and HPV 18 probes. Detection was performed via autoradiography after incubation for 24 h at Ϫ80°C. DNA from HPV 18 -positive HeLa cells, HPV 16 -positive Caski cells, and a negative control without any DNA served as controls during PCR and hybridization procedures.
Biopsy specimens were fixed in buffered formalin and embedded in blocks of paraffin within an hour of their collection by the pathology laboratory at each institution using a standard protocol. For histopathologic diagnosis, 4 sets of 3 adjacent sections were cut at 4 m and separately stained with hematoxylin and eosin and thionin-Feulgen. Because 2 to 4 biopsies were performed in each patient, it was possible for 1 patient to have multiple diagnoses. Therefore, we chose the worst diagnosis for each patient as the "true" disease status. In the present study, however, classification into either the high-or low-risk population was based solely on each participant's Papanicolaou smear history. Thus, biopsies here serve to demonstrate that the high-risk population truly has a greater prevalence of disease.
Statistical Analysis
Differences in demographics by screening or diagnostic population were determined by 2 test for categorical variables or t test for continuous variables using a commercially available statistical software package (SPSS, Inc., Chicago, Illinois). Prevalence ratios were used to assess the impact of each variable on the level of risk.
Logistic regression modeling was performed using the Hosmer and Lemeshow goodness-of-fit test. 10 A list of potential covariates was established based on the study hypothesis and suggestions from the literature. 11, 12 These included race, age, annual household income, education level, employment status, marital status, ever smoking, alcohol use, history of genital infections, menopausal status, parity, current OC use, current use of condoms, HPV status by Hybrid Capture II, type of HPV DNA present, and the worst histologic diagnosis. Variables significant at the 0.20 ␣ level in univariate analyses were considered for inclusion in the final multivariate model. Proper functional form (eg, linear, dichotomous) was determined using the quartile method. 10 Diagnostic graphs (residuals, leverage, and influence) were plotted to assess the fit of the final model for all covariate patterns. Any covariate patterns found to have unnecessary influence on the model were excluded from the analysis. Regression analyses were per- 
RESULTS
In all, 850 diagnostic and 1000 screening patients were recruited. As shown in Table I , in every classification of disease considered abnormal, ie, the histology diagnosis is greater than or equal to HPV-associated changes, prevalence ratios (PRs) were in fact greater in the diagnostic population, thus lending support to our classification scheme. It should be noted that biopsy specimens showing atypia were classified as normal. Recently, atypia has represented a growing problem of being overcalled by pathologists. This may help explain the large percentages of potentially confounding atypia results in our data. Any presence of disease in the screening population, as evidenced by negative findings on a Papanicolaou smear history and positive findings on a biopsy, may be the development of a lesion after the smear was taken, a previously missed lesion, or a false-negative result. Likewise, any absence of disease in the diagnostic population, as evidenced by a history of positive findings on a Papanicolaou smear and negative findings on a biopsy, may represent the regression of a lesion, an overcalled smear, or a small lesion missed by the biopsy.
Prevalence of HPV Infection
When considering the results from Hybrid Capture II, the diagnostic population was more positive for both low-and high-risk HPV types (PR ϭ 1.67 and 4.79, respectively; P Ͻ 0.0001) compared with the screening population. PCR results were similar, with the diagnostic group having a significantly higher prevalence of HPV 16 (PR ϭ 1.64, P Ͻ 0.0001) compared with the screening group. The diagnostic group was also more likely to be HPV consensus positive and HPV 18 positive; however, the difference in HPV 18 positivity was not statistically significant (P Ͻ 0.473). Table II summarizes the results of the risk factor interview. A greater percentage of the diagnostic population was white, Asian, Native American, or other race (P Ͻ 0.0001) compared with the screening population. The diagnostic population was also younger, with a mean age of 36.6 years compared with 44.1 years, yielding a difference of 7.5 years (P Ͻ 0.0001). The age range in the 2 groups was similar: 18 to 85 years for the diagnostic population and 18 to 80 years for the screening population. Finally, women in the diagnostic population were more likely to be born in the United States, Canada, or China.
Demographic and Epidemiologic Differences
Annual household income was analyzed using equivalent income brackets in the currency of the participant's home country (US dollars or Canadian dollars). Women in the diagnostic population were more like to report an annual income in the lowest income bracket ($0 -$19,999), whereas women in the screening population were more likely to report a higher annual income. There was no significant difference in the educational level of the 2 populations; however, more women in the screening population tended to have a college or advanced degree. Employment status was similar for both groups, except for a significantly higher proportion of students in the diagnostic population. This seems to account for the overall significant difference in employment status between the 2 populations. Women in the diagnostic population were also more likely to be single or divorced/separated compared with the screening population (P Ͻ 0.0001).
Table III summarizes the proportional risks as calculated. A higher proportion of the diagnostic population reported having ever smoked (PR ϭ 1.31, P Ͻ 0.0001). Among smokers, the screening population reported a longer period of smoking; however, this may be due to the screening population being older than the diagnostic population. More women in the diagnostic population also reported any alcohol use (72.4% vs 64.6% in the screening population).
Women in the diagnostic group were also more likely to report a history of genital infections (PR ϭ 1.62, P Ͻ 0.0001) compared with the screening group. The infections included were trichomoniasis, yeast infection, bacterial vaginosis, Gardinella vaginalis, gonorrhea, syphilis, genital herpes, genital warts, and Chlamydia trachomatis.
Women in the diagnostic population were more likely premenopausal, whereas women in the screening population tended to be either perimenopausal or postmenopausal (P Ͻ 0.0001). There was no statistically significant difference in the mean age at menarche between the 2 groups (12.6 years in the diagnostic population compared with 12.7 years in the screening population).
In our population, parity appeared to have a protective effect because the diagnostic population reported a lower average number of births (1.3 vs 1.7 in the screening population, P Ͻ 0.0001). This seems to be opposite of the effects of parity reported in other studies. Muñoz et al 13 reported that high parity (Ն7 births) actually increased the risk of squamous cell carcinoma of the cervix, after controlling for HPV positivity. Given that parity decreases as society progresses, this result may be a consequence of the screening population being on average 7.5 years older than the diagnostic population, the urban setting, or the inclusion of multinational participants. Current OC use was more prevalent in the diagnostic population (PR ϭ 3.52, P Ͻ 0.0001). Finding of previous studies are inconclusive, although the general consensus is that OC use increases the risk of cervical carcinoma. [14] [15] [16] [17] However, these studies have been unable to control for other factors, such as an avoidance of other types of contraceptives (eg, condoms) and a correlation of OC users with more lifetime sexual partners. 18, 19 Moreno et al 17 showed a positive association between OC use and cervical cancer risk when controlling for HPV status; however, Kjellberg et al 16 found that a similar correlation lost significance when HPV status was taken into account.
Women in the diagnostic population reported an earlier age at the start of sexual activity (mean, 17.47 years vs 18.95 years in the screening group; P Ͻ 0.0001), and more lifetime sexual partners (mean, 9.05 vs 6.91, respectively). However, this result was statistically insignificant (P Ͻ 0.122), most likely due to the large range of sexual part- ners reported in each group (0 -500 and 0 -1000 for the diagnostic and screening populations, respectively). Table III presents both univariate and multivariate logistic regression results. This model revealed that nonwhite race, having more than a high school education, and peri-or postmenopausal status were associated with the screening population. A history of genital infections, current OC use, HPV positivity (by Hybrid Capture II and consensus PCR), and histology at a clinic visit were important predictors of being in the diagnostic group. Interestingly, pre-and postmenopausal women were the most likely to be in the diagnostic group. This phenomenon likely represents the bimodal distribution of cancer cases that are seen in young women and older women. Also, we saw a similar 2-fold increase in the likelihood of being in the diagnostic group for women who reported a history of genital infections or current OC use, both of which have previously been reported to increase a woman's risk of cervical cancer. We also saw an increase in the odds of being in the diagnostic group with increasing levels of dysplasia. This lends strength to our hypothesis that women in the diagnostic group were more at "risk" for dysplasia than women in the screening group. Taken together, our results suggest that, within our study population, premenopausal urban white women who have less than a high school education, have a history of genital infections, currently use OCs, are HPV positive, and have an abnormal level of disease by histology are the most likely to require additional diagnostic services. An overall goodness-of-fit test was performed and a receiveroperating characteristic curve plotted ( Figure) of the most parsimonious model.
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Modeling the Characteristics of the High-Risk Woman
DISCUSSION
Here we show that women who present with a history of abnormal findings on Papanicolaou testing for diagnostic purposes are more likely to be urban white, less educated, have a history of gen-ital infections, be premenopausal, be current users of OCs, and, as would be expected, HPV positive and have cervical dysplasia compared with women who present for cervical screening and have no history of abnormal findings on Papanicolaou testing. This is among the first reports, to our knowl- 
Figure.
Receiver-operating characteristic (ROC) curve for the final logistic model.
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edge, to show meaningful comparisons of 2 clinical populations for screening and diagnosis. This is a great strength of our analysis because we show important differences in the characteristics of these 2 populations: those who present for screening purposes and those who present for diagnostic and treatment purposes. Most studies reported to date compared a histologically "normal" population with one with dysplasia, at varying levels. To make the greatest difference in screening women for cervical dysplasia, we must be able to identify those women who could be screened versus those who might need extra scrutiny.
Our current results suggest that simple demographic characteristics could be used to identify women at increased risk for the development of dysplasia who might need further evaluation and immediate care. Current cervical cancer screening recommendations in the United States are universally based on age but have been recently updated to include HPV DNA testing. 20 The inclusion of HPV DNA testing into routine screening will, it is hoped, lower the number of women unnecessarily treated because of false-positive results on testing; however, the expense of the assay still leaves some room for improvement. In addition, the currently approved HPV DNA test does not provide viral type-specific results, and it has been shown that there are differences in prognosis of cervical lesions based on the infecting HPV type. 21 Therefore, the identification of factors related to individual screening need could help to better triage women for standard screening methods versus emerging real-time screening techniques.
The introduction of the Bethesda System for cervical cytology was intended to reduce the variation in classifying cervical abnormalities; however, the correct classification of atypia is still questioned and often revised. 22 The term atypical squamous cells of undetermined significance (ASCUS) was established to categorize abnormalities that were more than "reactive" but markedly less than a diagnosis of squamous intraepithelial lesion. It is also recognized that the categorization of ASCUS does lead to more intensive follow-up of patients. Two new categories, atypical squamous cells, cannot exclude high-grade lesion (ASC-H) and atypical glandular cells of undetermined significance (AGCUS), have also been established and are treated as highgrade disease. It is hoped that ASC-H will prompt even more rapid determination of more severe disease, if it exists. A recent report showed that in Ͼ50% of patients with ASC-H, a high-grade squamous intraepithelial lesion developed on followup, most within 1 year of the ASC-H diagnosis. 23 Given the constant desire to better our classification schemes, studies such as the one we present here become important in identifying women who deserve and require more intensive screening and potential therapeutic intervention.
A strength of our current study is the large number of women in each arm, screening (n ϭ 1000) and diagnostic (n ϭ 850). The current study was also conducted at multiple centers in the United States and Canada, allowing for easier generalization of results. Our team was also able to recruit races in proportion with the demographics of the United States. Another major strength of our study is the systematic way in which pathology was determined. Overall disease status was based on a consensus diagnosis based on multiple biopsy specimens graded by several expert pathologists, if necessary. An analysis of our interpathologist and intrapathologist readings found high levels of agreement. 24 A limitation in our study is the inability to analyze specific HPV types other than HPV 16 and HPV 18. However, these 2 types represent the majority of lesions in our population, and, as technologies advance to analyze more types in a costeffective manner, we will adapt our protocol accordingly. We are very interested in type-specific differences in disease progression, especially as this might apply to our international population. Although our population may be representative of the general population in terms of race, we have an unusually large number of urban women, likely due to the location of our clinics. Another limitation of our study is that we have 2-year follow-up data for all of our Canadian patients, whereas we have these data for only 50% of our American patients.
